AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03758924
Drug: ANAVEX2-73
RxNorm normalized name: ANAVEX2-73
DrugBank: Blarcamesine (DB05592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution
Trial: NCT02396628
Drug: Experimental intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
Trial: NCT01831479
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of olmesartan 40mg tablet QD for 7 consecutive days
Trial: NCT01279213
Drug: paliperidone clozapine
RxNorm normalized name: Paliperidone
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: dose 3 to 12 mg paliperidone ER daily during 12 weeks
Trial: NCT02864030
Drug: ERIBULIN MESYLATE
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin.
Trial: NCT04227704
Drug: Ketamine 50 MG/ML
RxNorm normalized name: ketamine 50 MG/ML
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
Trial: NCT04227704
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 0.9% Sodium Chloride (N/S)
Trial: NCT00695032
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00695032
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02760277
Drug: Vamorolone 0.25 mg/day/day
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 0.25 mg/kg/day daily for 24 weeks.
Trial: NCT02760277
Drug: Vamorolone 0.75 mg/day/day
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 0.75 mg/kg/day daily for 24 weeks.
Trial: NCT02760277
Drug: Vamorolone 2.0 mg/day/day
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 2.0 mg/kg/day daily for 24 weeks.
Trial: NCT02760277
Drug: Vamorolone 6.0 mg/day/day
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 6.0 mg/kg/day daily for 24 weeks.
Trial: NCT02880540
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02880540
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002888
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002888
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04501211
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal sancuso patch
Trial: NCT03103451
Drug: BCD-121
RxNorm normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02117258
Drug: Z-360
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
Trial: NCT00799071
Drug: posaconazole (PSZ)
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
Trial: NCT00978627
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
Trial: NCT00978627
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
Trial: NCT00978627
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
Trial: NCT05718466
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02247557
Drug: Liposome encapsulated BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
Trial: NCT02247557
Drug: BOTOX 200U in normal saline
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
Trial: NCT00905515
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintain on cyclosporine at target trough level of 50-250 ng/mL.
Trial: NCT00905515
Drug: Prograf (Tacrolimus)
RxNorm normalized name: tacrolimus Injection [Prograf]
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
Trial: NCT03647488
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 400 mg (tablets) orally taken twice daily
Trial: NCT03647488
Drug: Spartalizumab
RxNorm normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab 400 mg via intravenous infusion once every 28 days
Trial: NCT03647488
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
Trial: NCT03460678
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
Trial: NCT03460678
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
Trial: NCT01268163
Drug: Hospira Docetaxel Injection
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-100 mg/m\^2 IV
Trial: NCT02559167
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
Trial: NCT00174824
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00150423
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03046108
Drug: blind injection of Mepivacaine
RxNorm normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blind injection of 1 cc of Mepivacaine Normon 2% ®
Trial: NCT03046108
Drug: blind injection of Triamcinolone
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blind injection of 40 mg of triamcinolone (trigon depot ®)
Trial: NCT03046108
Drug: guided injection of mepivacaine
RxNorm normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
Trial: NCT03046108
Drug: guided injection of Triamcinolone
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
Trial: NCT03289429
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
Trial: NCT03289429
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
Trial: NCT03037931
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Iron
Trial: NCT04764643
Drug: N-acetylcysteine solution
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Trial: NCT04764643
Drug: sodium thiosulfate solution
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
Trial: NCT01834547
Drug: Drugs use: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablets
Trial: NCT00606125
Drug: Nexavar (Sorafenib, BAY43-9006)
RxNorm normalized name: Nexavar
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
Trial: NCT01834547
Drug: Drug use: modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg tablets
Trial: NCT00534144
Drug: sodium ferric gluconate complex in sucrose injection
RxNorm normalized name: sodium ferric gluconate complex
DrugBank: Sodium ferric gluconate complex (DB09517)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
Trial: NCT03418896
Drug: human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single injection of a standard dose
Trial: NCT03505034
Drug: Umbilical Cord Mesenchymal Stem Cells
RxNorm normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
Trial: NCT00604786
Drug: omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Trial: NCT02698436
Drug: 2.5% Benzoyl Peroxide Treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The BPO treatment is applied twice daily, once in the morning and once in the evening
Trial: NCT03529422
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg IV every 3 weeks for 6 cycles
Trial: NCT01621737
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 42 IU BID for six weeks
Trial: NCT01621737
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 84 IU BID for six weeks
Trial: NCT01663389
Drug: GSK1322322 1000 mg containing radioactive 14C-GSK1322322
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
Trial: NCT01663389
Drug: GSK1322322 1200 mg containing radioactive 14C-GSK1322322
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
Trial: NCT01516138
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Trial: NCT00913341
Drug: Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913341
Drug: Alprazolam Tablets, 1 mg (The Upjohn Company)
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03147404
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
Trial: NCT00909337
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x62.5mg for 4 weeks, then 2x125mg
Trial: NCT00910689
Drug: Propranolol or nadolol
RxNorm normalized name: Nadolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
Trial: NCT00032773
Drug: pentostatin for injection
RxNorm normalized name: Pentostatin for Injection
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01103323
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Trial: NCT03791905
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy drug
Trial: NCT03791905
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chemotherapy drug
Trial: NCT03791905
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy drug
Trial: NCT03791905
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy drug
Trial: NCT03221023
Drug: Vancomycin Hydrochloride
RxNorm normalized name: Vancomycin Hydrochloride
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
Trial: NCT03221023
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individuals in the control arm will receive intrawound saline solution
Trial: NCT00551590
Drug: Sitagliptin tablet
RxNorm normalized name: Sitagliptin Tablets
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg PO for three days.
Trial: NCT00551590
Drug: Exendin(9-39) infusion
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin(9-39) IV on two consecutive study days.
Trial: NCT02343224
Drug: Pegylated interferon alpha-2b
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
Trial: NCT01081353
Drug: Aspirin Migraine
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One effervescent tablet under fasting conditions
Trial: NCT00071747
Drug: lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00618527
Drug: mycophenolate mofetil (Cellcept)
RxNorm normalized name: MYCOPHENOLATE MOFETIL (CELLCEPT) 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gram po, bid
Trial: NCT00618527
Drug: human interferon beta 1a (Rebif)
RxNorm normalized name: Interferon beta-1a (recombinant human)
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44mcg sq injection every other day
Trial: NCT03339700
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
Trial: NCT03339700
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
Trial: NCT00098332
Drug: forodesine hydrochloride
RxNorm normalized name: Forodesine hydrochloride
DrugBank: Forodesine (DB06185)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT00189488
Drug: Palifermin
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an intravenous (IV) bolus.
Trial: NCT01081353
Drug: Aspirin Aspro
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One effervescent tablet under fasting conditions
Trial: NCT02145234
Drug: BMS-986089
RxNorm normalized name: Bms-986089 (fully human anti-myostatin adnectin)
DrugBank: Talditercept alfa (DB16337)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02145234
Drug: Placebo matching with BMS-986089
RxNorm normalized name: Bms-986089 (fully human anti-myostatin adnectin)
DrugBank: Talditercept alfa (DB16337)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02900742
Drug: Gemcitabine®
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops.
Trial: NCT02900742
Drug: Pemetrexed®
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops.
Trial: NCT02900742
Drug: Docetaxel®
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
Trial: NCT00507195
Drug: Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00119210
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no